161 related articles for article (PubMed ID: 12712468)
1. Physician attitudes toward cytotoxic chemotherapy use in patients with advanced prostate carcinoma.
Oh WK; Tully P; Kantoff PW; Regan MM
Cancer; 2003 May; 97(9):2171-9. PubMed ID: 12712468
[TBL] [Abstract][Full Text] [Related]
2. Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
Meluch AA; Greco FA; Morrissey LH; Raefsky EL; Steis RG; Butts JA; Hainsworth JD;
Cancer; 2003 Nov; 98(10):2192-8. PubMed ID: 14601089
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
Smith DC; Chay CH; Dunn RL; Fardig J; Esper P; Olson K; Pienta KJ
Cancer; 2003 Jul; 98(2):269-76. PubMed ID: 12872344
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant treatment recommendations in older women with breast cancer: a survey of oncologists.
Hurria A; Naeim A; Elkin E; Limaye S; Grover A; Hudis C; Pearce C; Robson M
Crit Rev Oncol Hematol; 2007 Mar; 61(3):255-60. PubMed ID: 17098441
[TBL] [Abstract][Full Text] [Related]
5. Lung cancer treatment in New Zealand: physician's attitudes.
Christmas T; Findlay M
N Z Med J; 2004 Jun; 117(1196):U931. PubMed ID: 15280935
[TBL] [Abstract][Full Text] [Related]
6. Oncologists' and physiatrists' attitudes regarding rehabilitation for patients with advanced cancer.
Spill GR; Hlubocky FJ; Daugherty CK
PM R; 2012 Feb; 4(2):96-108. PubMed ID: 22373458
[TBL] [Abstract][Full Text] [Related]
7. Quantification of disseminated tumor cells in the bloodstream of patients with hormone-refractory prostate carcinoma undergoing cytotoxic chemotherapy.
Schmidt U; Bilkenroth U; Linné C; Fuessel S; Kraemer K; Froehner M; Wirth MP; Meye A
Int J Oncol; 2004 Jun; 24(6):1393-9. PubMed ID: 15138579
[TBL] [Abstract][Full Text] [Related]
8. Policy versus practice: comparison of prescribing therapy and durable medical equipment in medical and educational settings.
Sneed RC; May WL; Stencel C
Pediatrics; 2004 Nov; 114(5):e612-25. PubMed ID: 15520092
[TBL] [Abstract][Full Text] [Related]
9. Dental screening and referral of young children by pediatric primary care providers.
dela Cruz GG; Rozier RG; Slade G
Pediatrics; 2004 Nov; 114(5):e642-52. PubMed ID: 15520094
[TBL] [Abstract][Full Text] [Related]
10. [What is the objective of second-line chemotherapy after failure of first-line chemotherapy in hormone-resistant metastatic prostate?].
El Demery M; Pouessel D; Avancès C; Iborra F; Rebillard X; Faix A; Ségui B; Delbos O; Ayuso D; Culine S
Prog Urol; 2006 Jun; 16(3):320-3. PubMed ID: 16821344
[TBL] [Abstract][Full Text] [Related]
11. Impact of patient age and comorbidity on surgeon versus oncologist preferences for adjuvant chemotherapy for stage III colon cancer.
Krzyzanowska MK; Regan MM; Powell M; Earle CC; Weeks JC
J Am Coll Surg; 2009 Feb; 208(2):202-9. PubMed ID: 19228531
[TBL] [Abstract][Full Text] [Related]
12. What information are urologists extracting from prostate needle biopsy reports and what do they need for clinical management of prostate cancer?
Descazeaud A; Rubin MA; Allory Y; Burchardt M; Salomon L; Chopin D; Abbou C; de la Taille A
Eur Urol; 2005 Dec; 48(6):911-5. PubMed ID: 16140457
[TBL] [Abstract][Full Text] [Related]
13. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
[TBL] [Abstract][Full Text] [Related]
14. Factors influencing identification of and response to intimate partner violence: a survey of physicians and nurses.
Gutmanis I; Beynon C; Tutty L; Wathen CN; MacMillan HL
BMC Public Health; 2007 Jan; 7():12. PubMed ID: 17250771
[TBL] [Abstract][Full Text] [Related]
15. Physician attitudes toward strategies to promote the adoption of medical evidence into clinical practice.
Borenstein J; Chiou CF; Henning JM; Wilson A; Hohlbauch AA; Richards MS; Ofman JJ; Weingarten SR
Am J Manag Care; 2003 Mar; 9(3):225-34. PubMed ID: 12643340
[TBL] [Abstract][Full Text] [Related]
16. Treatment considerations for persons with metastatic prostate cancer: survival versus out-of-pocket costs.
Matchar DB; McCrory DC; Bennett CL
Urology; 1997 Feb; 49(2):218-24. PubMed ID: 9037283
[TBL] [Abstract][Full Text] [Related]
17. Cancer prevention trials and primary care physicians: factors associated with recommending trial enrollment.
Battaglia TA; Ash A; Prout MN; Freund KM
Cancer Detect Prev; 2006; 30(1):34-7. PubMed ID: 16476525
[TBL] [Abstract][Full Text] [Related]
18. A study of discrimination within the medical community as viewed by obese patients.
Kaminsky J; Gadaleta D
Obes Surg; 2002 Feb; 12(1):14-8. PubMed ID: 11868290
[TBL] [Abstract][Full Text] [Related]
19. A survey of obstetrician-gynecologists concerning practice patterns and attitudes toward hormone therapy.
Power ML; Zinberg S; Schulkin J
Menopause; 2006; 13(3):434-41. PubMed ID: 16735940
[TBL] [Abstract][Full Text] [Related]
20. Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey.
Schrag D; Hanger M
J Clin Oncol; 2007 Jan; 25(2):233-7. PubMed ID: 17210946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
